Progress towards personalized medicine.

Personalized medicine is the tailoring of therapies to defined subsets of patients based on their likelihood to respond to therapy or their risk of adverse events. The advent of improved genomic tools has greatly hastened our understanding of the molecular pathology of diseases, enabling us to redefine disease at the molecular level. The development of molecularly targeted therapies, coupled with improved diagnostic criteria, holds the promise of delivering a new paradigm in drug development. But how far have we come, and how close is personalized medicine to delivering on its promise?

[1]  J. T. Jørgensen,et al.  New era of personalized medicine: a 10-year anniversary. , 2009, The oncologist.

[2]  Y. Horio,et al.  Gefitinib for the treatment of non-small-cell lung cancer , 2009, Expert review of anticancer therapy.

[3]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[4]  E. Abrahams,et al.  The Case for Personalized Medicine , 2009, Journal of diabetes science and technology.

[5]  Langreth,et al.  New era of personalized medicine: targeting drugs for each unique genetic profile , 1999, The oncologist.

[6]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[7]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[8]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Mack.  FDA holds court on post hoc data linking KRAS status to drug response , 2009, Nature Biotechnology.

[10]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[11]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[12]  P. Noyce,et al.  Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies , 2008, The Annals of pharmacotherapy.

[13]  Christos Hatzis,et al.  Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.

[14]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[15]  E. Van Cutsem,et al.  Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[17]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[18]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[19]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[20]  F. Monzon,et al.  Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Masahiro Fukuoka,et al.  Gefitinib in non-small cell lung cancer , 2005, Expert opinion on pharmacotherapy.

[22]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[23]  A. Floore,et al.  Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary , 2008, British Journal of Cancer.

[24]  Edd Fleming,et al.  The microeconomics of personalized medicine: today's challenge and tomorrow's promise , 2009, Nature Reviews Drug Discovery.

[25]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[26]  Janet Woodcock,et al.  Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.

[27]  J. T. Jørgensen.  Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development , 2008, Expert review of molecular diagnostics.

[28]  L M Hinman,et al.  The drug diagnostic co-development concept paper Commentary from the 3rd FDA-DIA-PWG-PhRMA-BIO Pharmacogenomics Workshop , 2006, The Pharmacogenomics Journal.

[29]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[30]  D. Joske.  Chronic myeloid leukaemia: the evolution of gene‐targeted therapy , 2008, The Medical journal of Australia.

[31]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[32]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[33]  H. Guchelaar,et al.  Clinical Implications of CYP 2 D 6 Genotyping inTamoxifen Treatment for Breast Cancer , 2008 .

[34]  K. Jain.  Applications of AmpliChip™ CYP450 , 2012, Molecular Diagnosis.

[35]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[36]  E. Hayden.  Personalized cancer therapy gets closer , 2009, Nature.

[37]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. V. D. van de Velde,et al.  Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.

[39]  J. Rockstroh,et al.  Maraviroc, risks and benefits: a review of the clinical literature. , 2008, Expert opinion on drug safety.

[40]  Ge Zhang,et al.  From Human Genetics and Genomics to Pharmacogenetics and Pharmacogenomics: Past Lessons, Future Directions , 2008 .

[41]  E. Van Cutsem,et al.  Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Ge Zhang,et al.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. , 2008, Drug metabolism reviews.